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AbstrAct
Background Biomarkers are important in the diagnosis, 
risk stratification and management of patients with heart 
failure (HF). The established biomarkers of myocardial 
stretch, brain natriuretic peptide (BNP) and amino (N) 
portion of BNP (NT-proBNP) have been extensively 
studied, and early analyses have demonstrated response 
to exercise training. Several other biomarkers have been 
identified over the last decade and may provide valuable 
and complementary information which may guide 
treatment strategies, including exercise therapy.
Methods A systematic search of PubMed, EMBASE 
and Cochrane Trials Register to 31 October 2017 was 
conducted for exercise-based rehabilitation trials in HF. 
Randomised and controlled trials that reported biomarkers, 
BNP, NT-proBNP, soluble ST2, galectin-3, mid-regional 
atrial natriuretic peptide, mid-regional adrenomedullin and 
copeptin, were included.
Results Forty-three studies were included in the 
systematic review, with 27 studies suitable for meta-
analyses. Data pooling was only possible for NT-proBNP 
and BNP. Meta-analyses of conventional training studies 
demonstrated a statistically significant improvement in 
NT-proBNP (pmol/L); mean difference (MD) −32.80 (95% 
CI −56.19 to −9.42), p=0.006 and in BNP (pmol/L); MD 
−17.17 (95% CI −29.56 to −4.78), p=0.007. Pooled data 
of non-conventional training failed to demonstrate any 
statistically significant improvements.
Conclusion Pooled data indicated a favourable effect 
of conventional exercise therapy on the established 
biomarkers, NT-proBNP and BNP; however, this was in 
contrast to a number of studies that could not be pooled. 
Limited evidence exists as to the effect of exercise training 
on emerging biomarkers.
IntRoduCtIon
Heart failure (HF) is a complex syndrome 
resulting from multiple conditions and 
underlying disorders and continues to be a 
significant burden on the healthcare system. 
Over the past three decades, an increasing 
number of studies have provided evidence 
on a range of benefits of exercise training in 
patients with HF.1–5 In patients with stable HF, 
exercise training is now a Class 1 recommen-
dation in HF guidelines.6 7 
Numerous pathways are involved in the 
development and progression of HF, and the 
discovery of biomarkers has and will hopefully 
continue to enhance our understanding of the 
pathophysiology.8 9 Circulating biomarkers 
are important in the diagnosis, risk strati-
fication and management of patients with 
HF.6 10 11 HF biomarkers tend to be classified 
according to the associated pathophysiolog-
ical processes.12 13 These include biomarkers 
of myocardial stretch, myocyte injury, 
fibrosis, matrix remodelling, inflammation, 
Key questions
What is already known about this subject?
 ► Early reviews indicate that exercise training may im-
prove brain natriuretic peptide (BNP) and amino (N) 
portion of BNP (NT-proBNP) in patients with heart 
failure (HF).
 ► A number of new trials have compared different 
types of conventional and non-conventional modes 
of training on BNP and NT-proBNP, but the optimal 
exercise prescription for reducing HF biomarkers is 
unknown.
What does this study add?
 ► The review updates the evidence in regard to the 
effect of exercise training on the established HF bio-
markers, BNP and NT-proBNP.
 ► Additionally, the response of a number of emerging 
biomarkers to exercise training has been investigat-
ed in patients with HF.
 ► The pooled analysis of conventional exercise train-
ing confirms improvements in BNP and NT-proBNP 
but demonstrates only limited evidence for non-con-
ventional training.
 ► Exercise training may also improve a number of 
other biomarkers representative of different patho-
physiological pathways involved in HF progression.
How might this impact on clinical practice?
 ► The exercise prescription for patients with HF can be 
optimised to improve biomarker profile and hence 
prognosis, providing a valuable resource for both 
clinicians and patients.
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oxidative stress, neurohumoral activation and renal 
dysfunction.10 12 13 Some biomarkers may bridge several 
pathophysiological processes. Currently, brain (B-type) 
natriuretic peptide (BNP) and its more stable inert form, 
the amino (N terminal) portion (NT-proBNP), markers 
of myocardial stretch, are recognised as the gold standard 
diagnostic and prognostic biomarkers in HF.6 7 11
Over recent decades, the role of circulating biomarkers 
in HF has evolved, with the emergence of a number of 
novel biomarkers.12 Among these biomarkers, suppres-
sion of tumorigenicity 2 (ST2) and galectin-3 (Gal-3) 
have demonstrated prognostic value in HF,14–17 and 
both are shown to be predictors of sudden cardiac 
death.18 19 In fact, the combination of the gold standard 
cardiac biomarkers of BNP/NT-proBNP with the newer 
biomarkers, such as soluble ST2 (sST2) and Gal-3, may 
improve risk stratification and prognosis.10 11 Other 
emerging biomarkers, mid-regional atrial natriuretic 
peptide (MR-proANP), mid-regional adrenomedullin 
(MR-proADM) and copeptin (CT-proAVP), have also 
been shown to have prognostic value in HF.9 20
In addition to their diagnostic and prognostic utility, 
biomarker profiles may prove beneficial in guiding HF 
therapy and improving treatment strategies,10 including 
the identification of patients with HF that may respond 
to exercise training.21–23 A 2010 meta-analysis24 suggested 
that exercise training had a favourable effect on both BNP 
and NT-proBNP. The results of which were confirmed 
by a 2011 individual patient data (IPD) meta-analysis, 
with a 37.4% and 28.3% reduction in NT-proBNP and 
BNP, respectively.25 Furthermore, BNP and NT-proBNP 
changes are correlated with changes in peak oxygen 
consumption (VO2peak).
25
The aim of this systematic review and meta-analysis was 
first to update the previous reviews as a number of addi-
tional studies have investigated BNP and/or NT-proBNP 
after training interventions. Second, given the emergence 
of new biomarkers in HF trials, we intended to add to the 
current literature the inclusion of a selected number of 
emerging biomarkers. Furthermore, differing to previous 
analyses, we expanded our review to include additional 
modalities of exercise therapy due to their increasing util-
isation in cardiac rehabilitation programmes and trials, 
which may provide alternatives for subgroups of patients 
with HF.
MetHods
search strategy
Potential studies were identified by conducting system-
atic searches of PubMed, EMBASE, CINHAL and the 
Cochrane Library of Controlled Trials up until 31 
October 2017. Searches included a mix of MeSH and 
free-text terms related to the key concepts of HF, exercise 
training and biomarkers. Additionally, systematic reviews, 
meta-analyses and reference lists of papers were hand 
searched for additional studies. One reviewer (MJP) 
conducted the search, and full articles were assessed for 
eligibility by two reviewers (MJP and NAS). A sample 
search strategy is presented in online supplementary files. 
Additional information was requested from five authors, 
with three responses.
study selection
Study type and participants
Randomised controlled trials (RCTs) and controlled trials 
of exercise therapy in patients with HF aged 18 years or 
older were included. HF type (ie, preserved, moderately 
reduced and reduced ejection fraction) was not consid-
ered as an inclusion or exclusion criteria. Only studies 
in which the authors specifically reported a patient diag-
nosis of HF were included. Studies assessing intervention 
effect on acute or decompensated HF were excluded.
Intervention
Exercise therapy included both conventional training, 
defined as aerobic training (AT), resistance training 
(RT) and combined AT and RT, and non-conventional 
modes of therapy, defined as Yoga, Tai Chi, stretching 
and the physical therapies of functional electrical stim-
ulation (FES) and inspiratory muscle training (IMT). 
Studies must have compared an exercise intervention to 
a usual care or education control group, with no formally 
prescribed exercise, and the duration of the exercise 
training must have been for a minimum of 4 weeks. 
Studies in which the participants had participated within 
a formal exercise rehabilitation programme within the 
last 6 months were excluded.
Outcomes
Studies were eligible to be included in the review if they 
reported one or more of the following outcomes in serum 
or plasma: BNP, NT-proBNP, cardiac troponin (cTnT), 
sST2, Gal-3, MR-proANP, MR-proADM and CT-proAVP.
Exclusions
Abstracts and non-English studies were excluded.
Data extraction
One reviewer (MJP) extracted the data. For each study, 
the following information was extracted: (1) author, year 
of publication and study design, (2) demographic and 
clinical characteristics, (3) exercise intervention char-
acteristics, (4) mean, SD, P value and main findings in 
regard to biomarkers and (5) details of assessment meth-
odology for biomarkers.
Data synthesis 
Statistical analyses were performed using Revman V.5.3 
(The Nordic Cochrane Centre, Copenhagen, Denmark). 
Individual meta-analyses were completed for continuous 
data by using the change in the mean and SD. Where the 
change in mean and SD was not reported, the change 
in mean was calculated by subtracting the preinterven-
tion mean from the postintervention mean, and Revman 
V.5.3 enabled calculations of SD using number of partici-
pants in each group, within or between group p values or 
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95% CI. Where p values were not provided, the SD of the 
mean difference (MD) was calculated using the formula: 
SD=square root [(SDpretreatment)
2+(SDpost-treatment)
2−(2 r 
×SDpretreatment×SDpost-treatment)], assuming a correlation coef-
ficient (r)=0.5, which is considered a conservative esti-
mate.26 Where data were not presented in text or tables 
and authors could not be reached, data presented in 
figures or reported in prior meta-analyses were extracted 
or accessed where possible.
Data were pooled for meta-analysis when two or more 
studies measured the same outcome and provided data 
in a format suitable for pooling. Where a study included 
multiple intervention groups and data were not provided 
for the combined intervention, data were entered sepa-
rately for each group, and the sample size of the control 
group was divided by the number of intervention groups 
to eliminate overinflation of the sample size. A random-ef-
fects inverse variance was used with the effects to measure 
MD. We used a 5% level of significance and a 95% CI 
to report change in outcome measures. Both BNP and 
NT-proBNP are commonly reported in SI units (pmol/L) 
or conventional units (pg/mL). Owing to large values 
associated with NT-proBNP, change data were converted 
from pg/mL to pmol/L for both NT-proBNP and BNP 
for presentation. Data were converted using the following 
factors: for NT-proBNP pmol/L=pg/mL ×0.118 and BNP 
pmol/L=pg/mL ×0.289.
For meta-analysis, we did not pool studies in which 
participants were clearly identified as only having heart 
failure with preserved ejection fraction (HFpEF), with 
other studies. We grouped studies for analysis according 
to conventional or non-conventional training modalities. 
For studies where the mean or SD of outcomes was not 
reported, but median, IQR or median and range were 
reported or where only a descriptive result was reported 
in regard to postintervention changes, a table and 
descriptive analysis are used.
Sensitivity analysis: In order to evaluate the influence of 
each study on the overall effect size, sensitivity analysis 
using the leave-one-out approach was conducted. Where 
SD was imputed, additional analyses were also carried 
out with different values for the correlation coefficient 
(r=0.75 and 0.25) to determine whether the overall 
results of the analyses were robust to the use of imputed 
correlation coefficients.
Heterogeneity and publication bias 
Heterogeneity was quantified using the I2 test.27 Values 
range from 0% (homogeneity) to 100% (high heteroge-
neity).27 Visual inspection of funnel plots28 assessed risk 
of publication bias.
Study quality
Study quality was assessed using the Tool for the Assess-
ment of Study Quality and Reporting in Exercise 
(TESTEX)29 by two authors (MJP and NK). In case of 
discrepancies, a third author (NAS) was consulted.
Results
The initial search generated a total of 3419 articles. After 
removal of duplicates and exclusion of articles based 
on abstract and title, 77 full-text articles remained for 
screening. Full screening resulted in 43 articles meeting 
the stated inclusion criteria (figure 1, Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses state-
ment), of which 27 studies were included in meta-anal-
yses. Details of full-text articles reviewed but excluded are 
provided, with reasons, in online supplementary table S1.
study and participant characteristics
A general description of included studies is provided in 
table 1. Of the 43 included studies, two30 31 studies were 
from the same trial but provided different biomarker 
information, and two32 33 studies contained an overlap 
of some participants, and data were combined into 
one dataset for meta-analysis to eliminate data overlap. 
Four22 34–36 of the studies were controlled but not 
randomised, one37 study randomised
participants between exercise intervention groups, 
but the control group was not randomised, one38 study 
was a retrospective analysis and all remaining studies 
were RCTs. Seven studies,30 31 39–43 representing six trials, 
included participants with a mean left ventricular ejec-
tion fraction (LVEF) >50%, one43 of which also included 
participants with LVEF <50%. Thirty-six trials included 
participants with mean LVEF <50%, and the mean LVEF 
of at least three44–46 studies indicates the inclusion of 
participants with a range of ejection fractions, reduced, 
mid-range and/or preserved ejection fraction. Base-
line NT-proBNP and BNP levels are provided in online 
supplementary table S2.
Intervention details
A detailed description of the interventions can be found 
in online supplementary table S3. Thirty-four studies 
used conventional exercise training, eight studies used 
non-conventional exercise training or therapy and one 
study combined non-conventional and conventional 
training. Intervention duration ranged from 4 weeks to 
9 months.
Biomarker assessment
Biomarker assay details are provided in online supple-
mentary table S4.
outcome measures
Amino (N) portion of BNP
Twenty studies reported on NT-proBNP. Two 
studies32 33 contained an overlap of some participants; 
to avoid possible duplication of data, these studies are 
represented as one dataset in the meta-analysis.
Meta-analysis
Overall, exercise demonstrated a statistically significant 
improvement in NT-proBNP (pmol/L); MD −47.83 
(95% CI −77.23 to −18.43), p=0.001 (figure 2).
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Conventional training
Pooled data from 10 studies32 33 35 37 43 47–52 (14 interven-
tion groups, 315 exercise participants and 212 controls) 
demonstrated a statistically significant improvement in 
favour of exercise, on NT-proBNP (pmol/L); MD −32.80 
(95% CI −56.19 to −9.42), p=0.006 (figure 2). Removal 
of the two intervention groups from one43 study, that 
included patients with a mean ejection fraction of 50%, 
improved the MD and statistical significance; MD −54.62 
(95% CI −74.36 to −34.87) pmol/L, p<0.00001 (online 
supplementary table S5). Apart from the study by Aksoy et 
al,43, sensitivity analysis using the leave-one-out approach 
revealed that the results remained relatively stable 
(figure 3). Sensitivity analyses conducted for different 
correlation coefficients for SD imputation did not result 
in any significant variance in overall results.
An additional six30 34 53–55 studies (table 2) could not be 
pooled due to differences in data reporting. Five studies 
presented data as median (IQR) or median (range), 
and one30 study only included patients with HFpEF. Two 
studies34 reported preintervention to postintervention 
NT-proBNP changes in exercise participants, but only 
one study reported a significant difference compared 
with control participants.
Non-conventional training
Pooled data from two45 56 studies (55 exercise partici-
pants and 59 controls) failed to demonstrate a statistically 
significant improvement in NT-proBNP (pmol/L); MD 
−157.47 (95% CI −327.64 to 12.70), p=0.07 (figure 2). 
Notably, the large size of the improvement was due to 
the inclusion of one study45 (figure 4). One42 additional 
study, in patients with HFpEF, not pooled, failed to 
demonstrate any significant change (table 2).
Brain natriuretic peptide
Twenty-two studies reported on BNP. Two32 33 studies 
contained an overlap of some participants; to avoid 
duplication of data, these studies are represented as one 
dataset in the meta-analysis.
Meta-analysis
Overall, exercise demonstrated a statistically significant 
improvement in BNP (pmol/L); MD −15.02 (95% CI 
−25.06 to −4.99), p=0.003 (figure 5).
Conventional training
Pooled data from 11 studies32 33 38 46 57–64 (12 interven-
tion groups, 268 exercise participants and 192 controls) 
Figure 1 PRISMA flow diagram. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses. 
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Table 1 Overview of studies included in the review
Study Design Participant characteristics Intervention
Ahmad et al53 RCT n=928 analysed, biomarker substudy HF ACTION Trial
E: n=477 (68% male), 59 (51–68) years, LVEF 25% (20–30)*
C: n=451 (73% male), 59 (51–68) years, LVEF 25% (20–31)
NYHA Class II–IV (<1% IV)
3 months
Aerobic
Aksoy et al43 RCT n=57 randomised, n=45 analysed
E1: n=15 (87% male), 64±9 years, LVEF 50%±7%
E2: n=15 (87% male), 60±7 years, LVEF 52%±5%
C: n=15 (87% male), 58±11 years, LVEF 52%±6%
NYHA Class II–III
10 weeks
Aerobic (E1: IAE, E2: CAE)
Antonicelli et al44 RCT n=343 randomised, n=313 completed 6 months
E: n=170 (61% male), 76±5 years, LVEF 48%±13%
C: n=173 (53% male), 78±6 years, LVEF 49%±13%
NYHA Class ≥2
6 months
Aerobic
Van Berendoncks et al34 Non-RCT
Cohort with control 
group
n=80 analysed
E: n=46 (70% male), 58±10 years, LVEF 17% (14–22)*
C: n=34 (59% male), 61±12 years, LVEF 19% (15–24)
NYHA Class II–III
4 months
Aerobic and combined
Billebeau et al22 Non-RCT
Cohort with control 
group
n=131 enrolled
E: n=107 (86% male), 59 (52–66) years, LVEF 30% (25–39)*
C: n=24 (79% male), 63 (53–72) years, LVEF 35% (30–40)
NYHA Class II–IV
4–6 months
Aerobic
Brubaker et al65 RCT n=59 randomised, n=44 analysed
E: n=30 (63% male), 70±5 years, LVEF 32%±9%
C: n=29 (69% male), 70±6 years, LVEF 30%±9%
NYHA Class II–IV (n=1 Class IV)
16 weeks
Aerobic
Butterfield et al58 RCT n=19 randomised, n=17 analysed
E: n=11 (82% male), 66±10 years, LVEF 34%±11%
C: n=6 (50% male), 75±12 years, LVEF 35%±14%
NYHA Class II–III
12 weeks
Combined
Conraads et al48 RCT n=17 randomised and analysed
E: n=8 (38% male), 57±2 years, LVEF 27%±5%
C: n=9 (56% male), 61±4 years, LVEF 28%±5%
NYHA Class III
4 months
Aerobic
Conraads et al35
 (2004)
Non-RCT
Cohort with control 
group
n=49 enrolled and analysed
E: n=27 (78% male), 59±2 years, LVEF 26%±1%
C: n=22 (68% male), 59±2 years, LVEF 26%±1%
NYHA Class II–III
4 months
Combined
Delagardelle et al37 RCT/non-RCT† n=60 randomised and analysed
E: n=45 (84% male), 59±6 years, LVEF 24%±5%
C: n=15 (87% male), 56±8 years, LVEF 25%±6%
NYHA Class II
~13.3 weeks Combined, 
aerobic or strength
Edelmann et al30
Ex-DHF pilot study
RCT n=67 randomised, n=64 analysed
E: n=44 (45% male), 64±8 years, LVEF 68%±7%
C: n=20 (40% male), 65±6 years, LVEF 67%±7%
NYHA Class II and III
12 weeks
Combined
Eleuteri et al54 RCT n=21 randomised and analysed
E: n=11 (100% male), 66±2 years, LVEF 28%±2%
C: n=10 (100% male), 63±2 years, LVEF 30%±2%
NYHA Class II
3 months
Aerobic
Fernandes-Silva et al23 RCT n=52 randomised, n=40 analysed
E: n=28 (50% male), 51±7 years, LVEF 30%±6%
C: n=16 (62% male), 48±7 years, LVEF 29%±7%
NYHA Class I–III
12 weeks
Aerobic
Continued
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Study Design Participant characteristics Intervention
Fu (2013)57 RCT n=45 randomised, n=40 analysed
E1: n=15 (67% male), 68%±5%, LVEF 38%±4%
E2: n=15 (60% male), 66±2 years, LVEF 39%±5%
C: n=15 (67% male), 68±3 years, LVEF 38%±4%
NYHA Class II–III
12 weeks
Aerobic (E1: AIT, E2: MCT)
Gary et al59 RCT n=24 randomised and analysed
E: n=12 (58% male), 59±11 years, LVEF 23%±8%
C: n=12 (42% male), 61±10 years, LVEF 27%±9%
NYHA Class II–III
12 weeks
Combined
Guazzi et al49 RCT n=26 randomised and analysed
E: n=18, C: n=8, 68±6 years, LVEF 37%±5%
NYHA Class II–III
24 weeks
Aerobic
Jónsdóttir et al46 RCT n=51 randomised, n=43 analysed
E: n=21 (76% male), 68±7 years, LVEF 42%±14%
C: n=22 (82% male), 69±5 years, LVEF 41%±14%
NYHA Class II–III
5 months
Combined
Karavidas et al66 RCT n=30 randomised and analysed
E: n=20 (80% male), 62±12 years, LVEF 28%±7%
C: n=10 (80% male), 64±8 years, LVEF 27%±5%
NYHA Class II–III
6 weeks
FES
Karavidas et al41 RCT n=30 randomised and analysed
E: n=15 (60% male), 69±9 years, LVEF 64%±8%
C: n=15 (60% male), 69±8 years, LVEF 63%±5%
NYHA Class II–III
6 weeks
FES
Kato et al67 RCT n=50 randomised and analysed
E: n=25 (80% male), 70±11 years, LVEF 28%±9%
C: n=25 (76% male), 70±8 years, LVEF 29%±9%
NYHA Class II–IV
4 weeks
Stretching
Kawauchi et al68 RCT n=53 randomised, n=35 analysed
E1: n=13 (46% male), 54±10 years, LVEF 30%±6%
E2: n=13 (62% male), 56±7 years, LVEF 28%±5%
C: n=9 (56% male), 56±7 years, LVEF 29%±7%
NYHA Class II–III
8 weeks
IMT+resistance
Kitzman et al40 RCT n=53 randomised, n=46 completed
E: n=26 (17% male), 70±6 years, LVEF 61%±5%
C: n=27 (9% male), 69±5 years, LVEF 60%±10%
NYHA Class II–III
16 weeks
Aerobic
Kitzman et al39 RCT n=51 randomised‡
E: n=26 (19% male), 68±6 years, LVEF 61%±6%
C: n=25 (20% male), 66%±5%, LVEF 63%±6%
NYHA Class II–III
20 weeks
Aerobic
Kobayashi et al61 RCT n=28 randomised and analysed
E: n=14 (86% male), 55±2 years, LVEF 29%±2%
C: n=14 (57% male), 62±2 years, LVEF 33%±2%
NYHA Class II and III
12 weeks
Aerobic
Krishna et al45 RCT n=130 randomised, n=92 analysed
E: n=44 (73% male), 49±6 years, LVEF 39%±5%
C: n=48 (67% male), 50±5 years, LVEF 40%±5%
NYHA Class I–II
12 weeks
Yoga
Malfatto et al60 RCT n=54 randomised and analysed
E: n=27 (70% male), 65±11 years, LVEF 31%±6%,
C: n=27 (74% male), 67±9 years, LVEF 33%±6%,
NYHA Class I and II
12 weeks
Aerobic
Table 1 Continued 
Continued
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Study Design Participant characteristics Intervention
Marco et al56 RCT n=22 randomised and analysed
E: n=11 (64% male), 69±9 years, LVEF 38%±16%
C: n=11 (91% male), 70±11 years, LVEF 36%±17%
NYHA Class II–III
4 weeks
IMT
Meyer et al50 RCT n=42 randomised and analysed
E: n=19 (79% male), 58±10 years, LVEF 29%±13%
C: n=23 (78% male), 54±9 years, LVEF 30%±11%
NYHA Class II–III
12 weeks
Aerobic
Nilsson et al55 RCT n=78 randomised, n=70 for BNP at follow-up
E: n=39 (77% male), 69±8 years, LVEF 30%±8%
C: n=39 (79% male), 72±8 years, LVEF 31%±10%
NYHA Class II–III
4 months
Aerobic
Nishi et al38 Retrospective 
analysis
n=45 randomised, n=31 analysed BNP
E: n=33 (88% male), 51±14 years, LVEF 18%±4%,
C: n=12 (83% male), 52±16 years, LVEF 18%±5%
NYHA Class II–III
3 months
Aerobic
Norman et al62 RCT n=42 randomised, n=39 analysed for BNP
E: n=20 (55% male), 56±3 years, LVEF 34%±1%
C: n=20 (60% male), 63±3 years, LVEF 32%±1%
NYHA Class II–IV
24 weeks
Combined
Palau et al42 RCT n=27 randomised, n=26 analysed
E: n=14 (50% male), 68 (60–76) years, LVEF 69% (63–77)*
C: n=12 (50% male), 74 (73–77) years, LVEF 76% (68–83)
NYHA Class II–IV
12 weeks
IMT
Parrinello et al63 RCT n=22 randomised and analysed
E: n=11 (73% male), 62±5 years, LVEF 39%±4%
C: n=11 (64% male), 63±5 years, LVEF 39%±4%
NYHA Class II–III
10 weeks
Aerobic
Passino et al32 RCT n=95 randomised, n=85 analysed
E: n=44 (89% male), 60±2 years, LVEF 35%±2%
C: n=41 (85% male), 61±2 years, LVEF 32%±2%
NYHA Class I–III
9 months
Aerobic
Passino et al33 RCT n=97 randomised, n=90 analysed
E: n=71 (87% male), 61±2 years, LVEF 35%±1%
C: n=19 (74% male), 63±2 years, LVEF 36%±2%
NYHA Class I–III
9 months
Aerobic
Sandri et al51
LEICA Study
RCT n=60 randomised and analysed
E1: n=15 (80% male), 50±5 years, LVEF 27%±1%
C1: n=15 (87% male), 49±5 years, LVEF 28%±1%
E2: n=15 (80% male), 72±4 years, LVEF 29%±2%
C2: n=15 (80% male), 72±3 years, LVEF 28%±2%
NYHA Class II–III
4 weeks
Aerobic
Maria Sarullo et al52 RCT n=60 randomised and analysed
E: n=30 (77% male), 53±6 years, LVEF 29%±5%
C: n=30 (74% male), 53±5 years, LVEF 29%±4%
NYHA Class II–III
12 weeks
Aerobic
Stevens et al64 RCT n=28 randomised, n=22 analysed
E: n=15 (67% male), 67±3 years, LVEF 39%±3%
C: n=7 (86% male), 64±6 years, LVEF 35%±2%
NYHA Class I–III
12 weeks
Combined
Trippel et al31
Ex-DHF pilot study post hoc 
analysis
RCT n=67 randomised, n=62 analysed for biomarkers
E: n=44 (45% male), 64±8 years, LVEF 68%±7%
C: n=20 (40% male), 65±6 years, LVEF 67%±7%
NYHA Class II–III
12 weeks
Combined
Table 1 Continued 
Continued
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demonstrated a statistically significant improvement in 
BNP (pmol/L) in favour of exercise; MD −17.17 (95% CI 
−29.56 to −4.78), p=0.007(figure 5). Sensitivity analyses 
using the leave-one-out approach revealed that the study 
by Gary et al59 impacted the size of the result, with an 
increase in MD and statistical significance with removal 
of this study (figure 6).
An additional five22 36 39 40 65 studies using conventional 
training (table 2) reported on BNP concentrations, but 
were not pooled due to differences in data reporting. 
Two22 36 studies reported data as median (IQR), two39 40 
studies were in participants with HFpEF and one65 study 
did not provide post-data but noted no change. Of the 
five studies, two22 36 reported decreases post-training in 
Study Design Participant characteristics Intervention
Wisløff et al47 RCT n=27 randomised, n=26 analysed
E1: n=9 (78% male), 77±9 years, LVEF 28%±7%
E2: n=9 (78% male), 74±12 years, LVEF 33%±5%
C: n=9 (67% male), 76±13 years, LVEF 26%±8%
12 weeks
Aerobic (E1: AIT, E2: MCT)
Yamamoto et al36 Non-RCT
Cohort with control 
group
n=18 enrolled and analysed
E: n=10 (90% male), 68 (64–70) years, LVEF 40% (37–43)*
C: n=8 (100% male), 70 (66–73) years, LVEF 37% (35–38)
NYHA Class II–III
6 months
Aerobic
Yeh et al69 RCT n=30 randomised and analysed
E: n=15 (67% male), 66±12 years, LVEF 24%±7%
C: n=15 (60% male), 61±14 years, LVEF 22%±8%
NYHA Class I–IV
12 weeks
Tai Chi
Yeh et al70 RCT n=100 randomised and analysed
E: n=50 (56% male), 68±12 years, LVEF 28%±8%
C: n=50 (72% male), 67±12 years, LVEF 30%±7%
NYHA Class I–III
12 weeks
Tai Chi
*Median (IQR).
†Randomised between three exercise groups, but control group not randomised.
 ‡Excludes diet and diet and exercise groups. 
AIT, aerobic interval training; BNP, brain natriuretic peptide; C, control; CAE, continuous aerobic training; DHF, diastolic heart failure; E, 
exercise; FES, functional electrical stimulation; IAE, aerobic interval training; IMT, inspiratory muscle training; LVEF, left ventricular ejection 
fraction; MCT, moderate continuous training; NYHA, New York Heart Association; RCT, randomised controlled trial.
Table 1 Continued 
Figure 2 Change (MD) in NT-proBNP (pmol/L) exercise versus control. For conversion to pg/mL=pmol/L divided by 0.118. AIT, 
aerobic interval training; CAE, continuous aerobic training; IAE, aerobic interval training; IHF, ischaemic heart failure; MCT, 
moderate continuous training; MD, mean difference; NHF, non-ischaemic heart failure; NT-proBNP, amino (N) portion of BNP.
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exercise participants with no change in controls. The 
two39 40 studies with HFpEF patents failed to find any 
change.
Non-conventional training
Pooled data from 4 studies66–69 (5 intervention groups, 
86 exercise participants and 59 controls) failed to 
Figure 3 Sensitivity analysis NT-proBNP (conventional training) with study removed. AIT, aerobic interval training; CAE, 
continuous aerobic training; IAE, aerobic interval training; IHF, ischaemic heart failure; MCT, moderate continuous training; NHF, 
non-ischaemic heart failure; NT-proBNP, amino (N) portion of BNP.
Table 2 Summary of findings of studies for NT-proBNP and BNP not pooled for meta-analysis
Study Design Intervention Analysed E/C Result
NT-proBNP
  Conventional training
   Ahmad et al19 RCT Aerobic 477/451 ↔ between groups
   Antonicelli et al44 RCT Aerobic 170/173 ↓ in E and significantly different to C
   Van Berendoncks et al34 Controlled Aerobic and combined 46/34 ↓ in E, but ↔ for ∆ between E and C
   Edelmann et al30 RCT Combined 44/20 ↔ in E or C
   Eleuteri et al54 RCT Aerobic 11/10 ↔ in E or C
   Nilsson et al55 RCT Aerobic 37/33 ↔ in E or C or between E and C
   Non-conventional
   Palau et al42 RCT IMT 14/12 ↔ in E or C or between E and C
BNP
  Conventional training
   Billebeau et al22 Controlled Aerobic 107/24 ↓ in E, ↔ in C
   Brubaker et al65 RCT Aerobic 23/21 ↔ between E and C
   Kitzman et al40 RCT Aerobic 26/27 ↔ between E and C
   Kitzman et al39 RCT Aerobic 26/25 ↔ in E or C
   Yamamoto et al36 Controlled Aerobic 10/8 ↓ in E, ↔ in C
   Non-conventional
   Karavidas et al41 RCT FES 15/15 ↔ for ∆ between E and C
   Yeh et al70 RCT Tai Chi 50/50 ↔ for ∆ between E and C
↓ statistically significant, ↔ no statistically significant change.
BNP, brain natriuretic peptide; C, control; E, exercise; FES, functional electrical stimulation; IMT, inspiratory muscle training; NT-
proBNP, amino (N) portion of BNP; RCT, randomised controlled trial.
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demonstrate a statistically significant improvement in 
BNP (pmol/L) exercise versus control; MD −9.92 (95% CI 
−28.03 to −8.20), p=0.28 (figure 5). Sensitivity analysis 
indicated that the study by Kawauchi et al68 affected the 
magnitude of the result (figure 7). Sensitivity analyses 
conducted for different correlation coefficients for SD 
imputation did not result in any significant variance in 
overall results. Two41 70 additional studies, using non-con-
ventional training, were not pooled. One70 reported data 
as median (IQR), and one41 was in patients with HFpEF, 
and both failed to demonstrate any significant change 
(table 2).
Cardiac troponin
Only a substudy of the HF ACTION trial reported on the 
effect of exercise training on cTnT levels compared with 
control participants, with no decreases in detectable levels 
of cTnT found in a cohort of participants from the trial.53
Galectin-3
Two studies compared Gal-3 in exercising and control 
participants. However, differences in data reporting did 
not allow for data pooling. Billebeau et al22 observed a 
statistically significant (p<0.001) median decrease of 
6.3% in the exercise group (n=107) with no change in 
control patients. While Fernandes-Silva et al23 reported 
no statistically significant difference in the mean change 
between exercise and control groups (p=0.69).
Soluble ST2
One study reported predata and postdata in regard to the 
effect of exercise training on sST2 levels. A statistically 
Figure 4 Sensitivity analysis NT-proBNP (non-conventional training) with study removed. NT-proBNP, amino (N) portion of 
BNP.
Figure 5 Change (MD) in BNP (pmol/L) exercise versus control. For conversion to pg/mL=pmol/L divided by 0.289. AIT, 
aerobic interval training; BNP, brain natriuretic peptide; LIPRT, low-intensity inspiratory training and peripheral resistance 
training; MCT, moderate continuous training; MD, mean difference MIPRT, moderate-intensity inspiratory and peripheral 
resistance training.
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significant (p=0.035) median decrease of 7.4% was 
observed post-training (n=97) by Billebeau et al,22 with no 
change in controls.
MR-proANP
Two studies reported on postintervention MR-proANP 
concentrations. Billebeau et al22 observed a statistically 
significant (p<0.001) median decrease of 16% post-
training (n=105), with no changes in control participants. 
In contrast, the post hoc analysis of the Ex-DHF pilot trial 
by Trippel et al31 noted no significant treatment effect in 
patients with HFpEF.
Mid-regional adrenomedullin
Two studies reported on postintervention MR-proADM 
concentrations. Billebeau et al22 observed a statisti-
cally significant (p=0.001) 6.4% median decrease in 
MR-proADM (n=103), with no changes in control partic-
ipants. In contrast, Trippel et al31 noted no significant 
treatment effect in patients with HFpEF.
Copeptin
One study by Trippel et al31 reported on CT-proAVP levels 
and failed to find any statistically significant change post-
training or compared with the control group in patients 
with HFpEF.
Figure 6 Sensitivity analysis BNP (conventional training) with study removed. AIT, aerobic interval training; BNP, brain 
natriuretic peptide; MCT, moderate continuous training.
Figure 7 Sensitivity analysis BNP (non-conventional training) with study removed. BNP, brain natriuretic peptide; LIPRT, low-
intensity inspiratory training and peripheral resistance training; MIPRT, moderate-intensity inspiratory and peripheral resistance 
training.
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study quality and reporting
A median TESTEX score of 8.5 out of 15 was obtained 
(range 6–12) (online supplementary table S6). Details of 
randomisation procedures, activity monitoring of control 
groups, adjustment of relative exercise intensity and 
provision of adequate details to calculate exercise energy 
expenditure were frequently lacking.
Heterogeneity and publication bias
Meta-analyses indicated a moderate level of heteroge-
neity. Visual inspection of the funnel plot showed slight 
asymmetry (online supplementary figures 1A,B).
dIsCussIon
This systematic review and meta-analysis compiled 
evidence from a large volume of studies assessing the effect 
of exercise therapy on established and a selected number 
of emerging biomarkers in patients with HF. Different to 
previous analyses, both conventional and non-conven-
tional modes of training were examined. When analysed 
separately, conventional training demonstrated a statis-
tically significant improvement in NT-proBNP and BNP, 
while pooled analyses of non-conventional training 
failed to demonstrate any significance. While BNP and 
NT-proBNP are raised across the HF spectrum, as levels 
may be lower in HFpEF, and in some instances close to 
normal, we excluded studies from pooled analyses that 
only included patients with HFpEF. However, it is highly 
likely that a number of other studies included in the anal-
yses with mean ejection fractions >40% would have also 
included patients with HFpEF, and it is possible that this 
could be reflected in the variability of the results.
The favourable result demonstrated in pooled anal-
yses of conventional training is consistent with previous 
reviews24 71 and a 2011 IPD meta-analysis.25 However, in 
contrast to our pooled results, of studies unable to be 
pooled, only two of seven studies for BNP, and two of the 
seven studies for NT-proBNP, indicated any significant 
change post-training or compared with controls. Further-
more, one of these studies was a sub-analysis of a large 
cohort from the HF ACTION trial, which found that 
levels of plasma NT-proBNP did not significantly improve 
after 3 months of AT,53 clearly contrasting with our result 
and previous analyses.24 25 71 However, adherence and 
participant crossover issues may have confounded the 
results of the HF ACTION trial. It is also possible that a 
longer intervention duration may have resulted in signif-
icant changes, as seen after 9 months by Passino et al,32 
although Sandri et al51 demonstrated significant decreases 
after only 4 weeks of endurance training.
emerging biomarkers
While BNP/NT-proBNP remains the gold standard HF 
biomarkers, with proven prognostic value, there are 
limitations. Age, gender, arrhythmias, obesity, renal 
function and comorbidities10 12 may all affect concen-
trations; hence, biomarkers less affected by these issues 
can provide valuable information. Furthermore, as 
biomarkers of myocardial stretch, BNP/NT-proBNP 
is only reflective of one pathophysiological pathway 
involved in HF; hence, biomarkers reflecting other path-
ways may provide new and valuable information and 
complement BNP/NT-proBNP. Both Gal-3 and sST2 
have been studied as emerging biomarkers in HF, and 
now have a Class IIB recommendation for risk stratifica-
tion by the American College of Cardiology/American 
Heart Association (ACC/AHA) (2013) guideline for HF 
management.7 Gal-3, a β-galactoside-binding lectin, plays 
a dominant role in inflammation, fibrosis and cardiac 
remodelling.10 12 sST2, a member of the interleukin 
(IL)-1 receptor family and defined as a ligand for IL-33, is 
considered a cardiovascular stress protein, associated with 
fibrosis, cardiac and vascular remodelling and inflamma-
tion.72 Initial evidence also indicates that other novel 
biomarkers, such as CT-proAVP20 73 74 and MR-proADM,75 
both biomarkers of neurohormonal activation, also have 
prognostic value in HF.
Current evidence does not allow for any conclusion as 
to the effect of exercise training on emerging biomarkers. 
However, the recent studies of Fernandes-Silva et al23 and 
Billebeau et al22 provide an interesting and perhaps prom-
ising platform on which future research can expand. 
Billebeau et al,22 in a non-randomised trial, observed a 
significant decrease in BNP, MR-proANP, MR-proADM, 
Gal-3 and sST2 in exercise training participants with 
no change in controls. Analysis according to change in 
VO2peak demonstrated that patients with an increase in 
VO2peak ≥14.5% (based on the median increase) experi-
enced a significant decrease in Gal-3, sST2, MR-proADM 
and MR-proANP compared with no significant biomarker 
change in participants with change in VO2peak <14.5%.
22 
Furthermore, given that BNP improved regardless of the 
change in VO2peak, they concluded that the addition of 
the newer biomarkers improved the clinical follow-up 
of rehabilitation.22 Overall, their results demonstrated 
that exercise training improves neurohormonal, inflam-
matory and fibrotic processes.22 Fernandes-Silva et al23 
observed no significant difference between exercise and 
control patients for change in Gal-3 or the proinflam-
matory markers (IL-6 and tumour necrosis factor-α); 
however, VO2peak significantly improved in participants 
with low baseline Gal-3 levels, compared with patients 
with high levels, with similar findings for the proinflam-
matory markers. These results suggesting biomarkers may 
predict a patient’s response to training.23 Interestingly, 
in a substudy of the HF ACTION trial, higher baseline 
ST2 levels were associated with a greater improvement in 
VO2peak at 3 months.
76
exercise capacity
Reduced exercise capacity is a major hallmark of HF, 
and NT-proBNP is a strong predictor of VO2peak.
77 
Changes in BNP and NT-proBNP have been correlated 
with changes in VO2peak and suggested therefore as a 
possible surrogate for evaluating training responses.25 
Only a minimal number of studies included in the review 
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reported associations between change in peak VO2peak 
and biomarkers. Ahmad et al53 did however observe that 
in patients in whom NT-proBNP levels decreased, there 
was an increase in VO2peak, despite finding no significant 
change in NT-proBNP. While Passino et al32 observed that 
changes in VO2peak correlated significantly with decreases 
in NT-proBNP and BNP. Recently, Billebeau et al found 
that of all the biomarkers they tested, for predicting 
change in exercise capacity, MR-proADM best correlated 
with VO2peak.
22 Given that adrenomedullin originates not 
only from the heart but also from multiple organs, tissues 
and blood vessels78 and that the mechanisms associated 
with improved exercise capacity in HF involve cardiac, 
vascular and skeletal muscle adaptations,79 a relationship 
between MR-proADM and improved exercise capacity 
makes sense.
Phenotype
Levels of BNP and NT-proBNP are elevated irrespective 
of ejection fraction; although they are generally lower in 
HFpEF compared with heart failure with reduced ejec-
tion fraction (HFrEF).80–82 Patients also present with 
elevated levels of a number of other biomarkers reflec-
tive of different pathophysiological pathways. Currently, 
there are limited data on the role of exercise training and 
biomarkers in HFpEF, and none of the HFpEF studies 
included in the review reported any significant changes 
in the biomarkers. Furthermore, it is likely that there exist 
different biomarker profiles for HFrEF and HFpEF.83 84 
Moving forward, these different biomarker profiles may 
provide valuable information for treatment strategies, 
including exercise.
exercise prescription
While moderate continuous training (MCT) has been the 
cornerstone of conventional HF training, over the past 
decade, the interest in high-intensity interval training 
(HIIT) has grown.85 Two studies included in the review 
that specifically incorporated HIIT and MCT groups 
for comparative purposes observed significant improve-
ments in BNP57 and NT-proBNP47 from HIIT, with no 
significant change from MCT. However, this is in contrast 
to the recent results of the larger, multicentre SMARTEX 
HF study, which failed to demonstrate any significant 
difference between HIIT and MCT after 12 weeks.86 
However, for comparisons, difficulty arises in regard to 
actual training intensities attained, and in SMARTEX, 
both actual HIIT and MCT intensities attained may have 
impacted the results, with patients training at lower and 
higher intensities than prescribed.86
To date, the majority of HF training studies have used 
conventional modes of training; however, not all patients 
can or are willing to participate in these activities. Women, 
for example, may be more likely to attend mind–body 
interventions, such as Tai Chi and Yoga, for cardiac reha-
bilitation purposes.87 88 Furthermore, both FES and IMT 
offer alternative modes of physical therapy, particularly 
in patients unable to participate in more conventional 
modalities. Individually, the included studies investi-
gating FES and IMT failed to demonstrate any significant 
change in BNP or NT-proBNP compared with control 
groups. However, the combination of these non-conven-
tional modes with conventional training may provide 
possible synergistic effects,89 as demonstrated by Caminiti 
et al90 with combined Tai Chi/endurance training and 
Adamopoulos et al89 with combined IMT/AT. Further-
more, other modes of non-conventional exercise therapy, 
such as weight-supported91 and robot-assisted92 exercise 
training, have demonstrated improvements in BNP and 
NT-proBNP in patients with HF and may be beneficial in 
some subgroups.
Clinical significance and future research
Biomarkers are used in HF clinical trials for a number of 
reasons,10 including establishment of inclusion criteria, 
outcome measures, explaining therapeutic efficacy and as 
a target for therapy.93 Biomarkers and biomarker panels 
may aid in identifying subgroups of patients with HF who 
may have a more favourable response to exercise therapy, 
distinguishing responders and non-responders21 23 in 
terms of specified outcomes including functional and 
long-term outcomes. Different biomarkers may provide 
further insight into the downstream molecular mech-
anisms associated with improvements from exercise 
training.21 It could be possible that different biomarker 
profiles respond differently to different intervention 
characteristics, such as intensity, perhaps allowing further 
tailoring of the exercise to the individual. Furthermore, 
biomarkers, with their prognostic utility, may provide 
useful postintervention information, indicating improve-
ments when other favourable outcomes may be absent. 
It remains premature to draw too many conclusions 
about the relationship between changes in emerging 
biomarkers and exercise training, and the utility of these 
biomarkers in HF is yet to be fully established, but it 
presents as an interesting and important area for future 
research.
Future research also needs to consider the clinical 
interpretation of changes in biomarkers given their 
biological variation.94 While NT-proBNP is considered 
to have high biological variation, the newer markers of 
sST2 and Gal-3 demonstrate a lower variation and there-
fore add value to their use.94 However, from an individual 
perspective in interpreting clinically meaningful changes 
in biomarkers, it is suggested that reference change values 
which indicate the percentage change necessary within 
an individual, reflective of a true change as opposed to 
biological variation, be used.94
strengths and limitations in the systematic review and meta-
analysis
To our knowledge, this is the first meta-analysis of BNP 
and NT-proBNP to include training studies beyond the 
conventional AT and RT modalities and the first review 
to consider exercise therapy and emerging biomarkers 
in HF. We aimed to provide a meta-analysis of studies 
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reporting on a selected number of established and 
emerging biomarkers. However, as biomarker distribu-
tions can be skewed, study data may often be presented 
as median (IQR) or median (range), which precludes it 
from inclusion in meta-analyses. Valuable information 
may be ignored if a number of studies are excluded; there-
fore, on initial review and identification of a number of 
studies that had examined biomarkers and reported data 
as median or provided a descriptive result, we felt that 
the inclusion of these studies would enhance the value 
of the review and analysis. Therefore, we included results 
of studies reporting data that were considered inappro-
priate for pooling and only provided a descriptive anal-
ysis of these studies.
Studies in which biomarkers were assessed as secondary 
outcomes may not have been adequately powered to 
detect significant differences in biomarkers. Further-
more, the studies included in the review reported a wide 
range of intervention durations, training frequency, 
session times and intensity. In regard to data pooling, we 
measured the difference between preintervention and 
postintervention means; however, in cases where exact 
p values within groups or 95% CI were not available, we 
imputed the SD, and hence statistical analysis depended 
on extrapolated data. However, our imputation was 
conservative, and sensitivity analyses were conducted for 
different correlation coefficients. Abstracts and trials not 
reported in English were excluded and could have led to 
publication bias.
ConClusIon
Pooled data of conventional training modalities indicated 
a favourable effect on the established HF biomarkers, 
NT-proBNP and BNP, contrasting with information from 
a number of non-pooled studies. Limited evidence exists 
in regard to exercise training and emerging biomarkers. 
Given the complex pathways involved in the onset and 
progression of HF, more research is required to establish 
exactly how established and emerging biomarkers can 
be used in exercise training in this population. The use 
of multiple biomarkers is an area of active research in 
HF, and future studies using biomarker panels may prove 
beneficial in guiding non-pharmacological therapy such 
as exercise by facilitating a more precise approach to 
exercise for subgroups of patients.
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